Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 9 Neoplasms 3 Endometrial Neoplasms 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Head and Neck Neoplasms 2 Esophageal Neoplasms 2 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Thrombocytopenia 1 Stomach Neoplasms 1 Solid Tumor, Adult 1 Recurrence 1 Rectal Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neutropenia 1 Neuroblastoma 1 Neoplasm Metastasis 1 Melanoma 1 Lung Neoplasms 1 Glioma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Cystadenocarcinoma, Serous 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1 Biliary Tract Neoplasms 1 Astrocytoma 1

Interventions

Cisplatin 18 pembrolizumab 12 Paclitaxel 9 Carboplatin 9 Radiotherapy 5 Gemcitabine 4 Fluorodeoxyglucose F18 4 Colposcopy 4 Brachytherapy 4 fludarabine 3 durvalumab 3 Surveys and Questionnaires 3 Radiation 3 Flow Cytometry 3 Cyclophosphamide 3 Biopsy 3 Bevacizumab 3 toripalimab 2 fludarabine phosphate 2 atezolizumab 2 aldesleukin 2 adavosertib 2 Zoledronic Acid 2 Topotecan 2 Nivolumab 2 Neoadjuvant Therapy 2 Microarray Analysis 2 Magnetic Resonance Spectroscopy 2 Interviews as Topic 2 Interleukin-2 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Uterine Cervical Neoplasms × niraparib × Clear all

NCT03644342 2024-09-03

NIVIX

Baylor College of Medicine

Phase 1/2 Terminated

4 enrolled 8 charts

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡